Question · Q3 2025
Lydia asked about any statistical work or study design changes made for the osteogenesis imperfecta program following the second interim analysis.
Answer
Howard Horn, Chief Financial Officer, stated he was not aware of any changes. Eric Crombez, Chief Medical Officer, confirmed that the statistical plan remains in place, and internal modeling and rework reinforced confidence in the existing plan for the final data readout.
Ask follow-up questions
Fintool can predict
RARE's earnings beat/miss a week before the call